Lilly, Boehringer collaborate on diabetes drugs
Tuesday, January 11, 2011 - 12:01
in Mathematics & Economics
(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.